Clinical Trials Logo

Clinical Trial Summary

Ovarian cancer (OC) has one of the highest mortality rates for female malignant tumors, attributed to advanced cancer stages upon diagnosis as well as a high recurrence rate. Piwi-interacting RNA-823 (piR-823) is a single-stranded non-protein coding RNA (ncRNA) star molecule in epigenetics research. Extensive cellular regulatory functions and aberrant expression of piR-823 have been implicated in carcinogenesis. Therefore, the findings of piwi-ncRNA dysregulated-expression in OC Egyptian female patients' cohort could be employed as a potential novel mechanism for OC precision, a step toward ncRNA-precision


Clinical Trial Description

1. Introduction Ovarian cancer (OC) represents one of the most aggressive female tumors worldwide and is the second most prevalent malignant tumor after breast cancer. In Egypt, OC represents the fourth most common female cancer. Current treatments become ineffective after several cycles of management due to the high recurrence rate, which is about 80-85%. Thus, it is urgent to explore novel targets for OC treatment [1]. OC represents a spectrum of diseases, not a single disease entity. Piwi-interacting RNA (piRNA) is a single-stranded non-coding RNA (ncRNA) with a nucleotide sequence of 23-35 that was discovered in mammalian germ cells. It has become a star molecule in non-coding RNA research due to its extensive cellular regulatory functions [3]. In recent years, many studies have found that piRNA is involved in tumor occurrence and development in many types of cancer, such as gastric cancer, liver cancer, lung cancer, breast cancer, and other cancers [4]. piR-52207 and piR-33733 participate in OC oncogenesis through involvement in numerous cell signaling pathways at the post-transcriptional level [5]. Nevertheless, the clinical significance and biological mechanisms of piRNAs in the progression of OC remain largely unknown. piR-823 was one of the first piRNAs recognized to be linked to malignancy and was identified in white blood cells, cancer cell lines, and blood plasma. piR-823 exhibits a pan-cancer expression pattern in various types of cancer, such as stomach, colon, breast, esophageal, liver, prostate, and renal cancer [6, 7]. More recently, piRNA-823 has been documented to be involved in tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma [3]. However, their functional mechanisms as well as their epigenetic regulatory role in OC have not been investigated Thus, investigating the regulatory role played by piR-823 could provide a way to explore the application of ncRNAs as a prognostic mechanism in OC, constituting a potential target for drug development RESEARCH OBJECTIVE(S) Investigate the expression level of piR-823 in OC tissue samples. Demonstrate the correlation between piR-823 and the progression of OC. Correlate piR-823 and OC clinicopathological characteristics 2. Subjects 2.1 Sample size and power of the study Sample size calculation is based on the previous study by (Jie Yin et al, 2017). Sample size estimation performed by G power* sample size online calculator (http://www.gpower.hhu.de/en.html), depending on two-sided confidence level 95%. The sample size to be able to reject the null hypothesis that the population means of the studied groups are equal with probability (power) (0.95) and type I error probability associated with this test of this null hypothesis is (0.05). 2.2 Study design Case-controlled retrospective observational study, mono-center. 2.3 Institutional Review Board (IRB) statement The Research Ethics Committee of the Faculty of Pharmacy, Ain Shams University, granted ethical permission to conduct the study. All participants (controls or patients) were fully cognizant of the purpose of the study and signed a written, ethically-approved, informed consent (I·C) form. This study was conducted in accordance to the Declaration of Helsinki Guidelines approved in 2013 2.4 Study participant 2.4.1 Patients group A total of 39 female, their age range (13- 75 years), patients diagnosed with primary malignant ovarian tumor were enrolled in the study. OC patients were treatment-naïve Egyptian patients' cohort admitted to the Gynecology and Obstetrics Department or the Oncology Dept., Ain Shams University Hospitals, Cairo, Egypt. Ovarian cancer tissue samples were collected during surgical resection and confirmed by postoperative pathological examinations. 2.4.2 Control group A total of 17 normal ovarian tissue samples were collected from patients with benign uterine diseases uterine such as myoma who underwent uterine and ovarian resection. Controls age range is 45-62 years For the patients' group (n = 39) a full history was recorded. Patient enrolled into the study If met the inclusion criteria and after giving their approval for participation in the study and signed the informed consent. Inclusion criteria; This study included newly diagnosed, untreated cases of histopathologically confirmed OC patients. Exclusion criteria; Individuals receiving chemotherapy, radiation, and patients with history of other cancer other than OC. Additionally, individuals with inadequate data or missing histopathological diagnoses. 2.4.3. Patients' demographic data and pathological data Patients were either in the reproductive, premenopausal, or postmenopausal phase. The patients' demographic data including age, menopausal status, ascites, and the patient full history, retrieved from the patients' medical records collected from Ain Shams Hospitals in addition to the original pathology reports of the following data (tumor site, tumor size, tumor type, lymph node metastasis, distant metastasis, tumor stage, and tumor grade) were obtained from the Department of Pathology, Ain Shams Hospitals. OC histological staging made in accordance to the International Federation of Gynecology and Obstetrics (FIGO) criteria 3. Methods 3.1 in silico analysis Databases mining for targeting pathways and functional enrichment analysis in addition to Binding interaction predications 3.2 Tissue samples Ovarian fresh tissue samples were collected from the controls and OC patients underwent surgical resection at the Department of Obstetrics and Gynecology, Ain shams university. All resected tissue samples were stored at -20°C after adding RNA Stabilization Reagent (Qiagen, Hilden, Germany) 3.3 Total RNA extraction and quantification Using the miRNeasy Mini kit (Cat. No.217004; Qiagen, Hilden, Germany) according to the manufacturer's protocol, from tissue samples, Total RNA extraction was done. The isolated RNA was eluted in 40 μL of RNase-free water. Then, the isolated RNA quantified using NanoDrop® 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA) the concentration and purity of all RNA samples were determined was stored at -80 °C in aliquots. 3.4 cDNA synthesis and measurement of piR-823 expression using qRT-PCR Total RNA will be reverse transcribed by miSCRIPT Kit (Qiagen, Hilden, Germany). Real-time PCR analysis subsequently performed using a miRcury LNA SYBR Green PCR Kit (Qiagen) as proposed by the manufacturer's instructions. The resulting cDNA was kept at -20 °C until quantification. qRT-PCR was used to measure the expression of the piR823 using the miRCURY LNA miRNA) endogenous control 3.5 cDNA synthesis and measurement of mRNA expression using qRT-PCR RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, IL, USA) was used for cDNA synthesis according the manufacture instructions. qRT-PCR made using Power SYBR Green PCR Master Mix (Thermo Scientific, Rockford, IL, USA). GAPDH primer was used as endogenous control. The RNA relative expression was computed and normalized as fold change using the cycle threshold (Ct) method (2--ΔΔCt). 3.6 Statistical analysis - Data will be collected, excel tabulated and tested for normality by Kolmogorov-Smirnov test. - Between-group differences in age variability will be compared by the χ2 test and by analysis of variance for age variability. Multivariate logistic regression with adjustments for age will be used to show the association between selected piR-823 expression and OC risk. - Normally distributed variables will be expressed as mean + (S.E.M) and analyzed using two samples independent t-test. Median (interquartile range) will be used to express nonparametric data, and subsequently analyzed using Mann Whitney U test. - Pearson's Chi-square analysis or Fisher's exact test employed to compare the difference of categorical variables. - For all analyses, a two-tailed P value of 0.05 or less considered statistically significant ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06320418
Study type Observational
Source Ain Shams University
Contact
Status Active, not recruiting
Phase
Start date June 15, 2022
Completion date June 2024

See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2